Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.56 |
| ▸ | RAB9A | P51151 | 8/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23226657 | 0.86 | PDK2 (0.51) | NPC1RAB9AHPGDSMN1; SMN2MAPT | |
| SCHEMBL30740721 | 0.85 | RAB9A (0.49) | NPC1RAB9AHPGDSMN1; SMN2MAPT | |
| SCHEMBL844384 | 0.85 | MEN1 (0.54) | RAB9AHPGDSMN1; SMN2MAPTLMNA | |
| SCHEMBL25483438 | 0.85 | NPC1 (0.56) | NPC1RAB9AHPGDSMN1; SMN2MAPT | |
| SCHEMBL393318 | 0.83 | NR4A2 (0.51) | HPGDMAPTABL1NR4A2ALDH1A1 | |
| SCHEMBL28809713 | 0.83 | NPC1 (0.59) | NPC1RAB9AHPGDSMN1; SMN2MAPT | |
| SCHEMBL28765390 | 0.83 | NPC1 (0.55) | NPC1RAB9AHPGDSMN1; SMN2MAPT | |
| SCHEMBL28792279 | 0.83 | RAB9A (0.55) | NPC1RAB9AHPGDSMN1; SMN2MAPT | |
| SCHEMBL608814 | 0.82 | ABL1 (0.68) | NPC1RAB9AHPGDSMN1; SMN2MAPT | |
| SCHEMBL2884923 | 0.82 | PDK2 (0.57) | NPC1RAB9AHPGDSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6225514-B1 | A MIXTURE OF AN AROMATIC HYDROCARBON, ESTER, NITRILE OR HALOGENATED AROMATIC, A HALOGENATING AGENT AND A STABLE ACID,AND CORROSION RESISTANT, HETEROGENEOUS, SOLID ACID CATALYST OF ?DOPED? MIXED OXIDES; BY-PRODUCT INHIBITION | OCCIDENTAL CHEMICAL CORPORATION | 2001-05-01 | — | — | US | claimed |
| US-6124512-A | HETEROGENEOUS CATALYST. | OCCIDENTAL CHEMICAL CORPORATION (US) | 2000-09-26 | — | — | US | claimed |
| CN-116375684-B | AChE-EGFR double-target inhibitor and preparation method and application thereof | 中国药科大学 | 2024-03-26 | — | — | CN | disclosed |
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| CN-116375684-A | AChE-EGFR double-target inhibitor and preparation method and application thereof | 中国药科大学 | 2023-07-04 | — | — | CN | disclosed |
| US-20230150993-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-18 | — | — | US | disclosed |
| US-20230133817-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230133667-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230114674-A1 | ISOINDOLINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2023-04-13 | — | — | US | disclosed |
| EP-4095132-A1 | ISOINDOLINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Kangpu Biopharmaceuticals, Ltd. (CN) | 2022-11-30 | — | — | EP | disclosed |
| CN-115038694-A | Isoindoline derivative, pharmaceutical composition and application thereof | 康朴生物医药技术（上海）有限公司 | 2022-09-09 | — | — | CN | disclosed |
| US-20040157741-A1 | Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents | ELI LILLY AND COMPANY | 2004-08-12 | — | — | US | disclosed |
| EP-1442030-A1 | THIOPENE- AMD THIAZOLESULFONAMIDES AS ANTINEOPLASTIC AGENTS | ELI LILLY AND COMPANY (US) | 2004-08-04 | — | — | EP | disclosed |
| EP-1401806-A1 | BENZOYLSULFONAMIDES AND SULFONYLBENZAMIDINES FOR USE AS ANTITUMOUR AGENTS | ELI LILLY AND COMPANY (US) | 2004-03-31 | — | — | EP | disclosed |
| WO-2003068233-A1 | NICOTINAMIDE DERIVATIVES AND A TIOTROPIUM SALT IN COMBINATION FOR THE TREATMENT OF E.G. INFLAMMATORY, ALLERGIC AND RESPIRATORY DISEASES | PFIZER LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003035629-A1 | THIOPENE- AMD THIAZOLESULFONAMIDES AS ANTINEOPLASTIC AGENTS | ELI LILLY AND COMPANY (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2002098848-A1 | BENZOYLSULFONAMIDES AND SULFONYLBENZAMIDINES FOR USE AS ANTITUMOUR AGENTS | ELI LILLY AND COMPANY (US) | 2002-12-12 | — | — | WO | disclosed |
| US-6225514-B1 | A MIXTURE OF AN AROMATIC HYDROCARBON, ESTER, NITRILE OR HALOGENATED AROMATIC, A HALOGENATING AGENT AND A STABLE ACID,AND CORROSION RESISTANT, HETEROGENEOUS, SOLID ACID CATALYST OF ?DOPED? MIXED OXIDES; BY-PRODUCT INHIBITION | OCCIDENTAL CHEMICAL CORPORATION | 2001-05-01 | — | — | US | disclosed |
| US-6153651-A | Ortho-substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-11-28 | — | — | US | disclosed |
| US-6124512-A | HETEROGENEOUS CATALYST. | OCCIDENTAL CHEMICAL CORPORATION (US) | 2000-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157741-A1 | Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents | GLS2, GLS, MCL1 | NPC1 1432/4885RAB9A 1952/4885HPGD 3528/4885 |
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | PDE4A, PDE4B, PDE5A | NPC1 1428/4885RAB9A 604/4885HPGD 312/4885 |
| US-20230150993-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MKI67, MCL1, CCNI | NPC1 286/4885RAB9A 1818/4885HPGD 157/4885 |
| US-20230133817-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | NPC1 1905/4885RAB9A 2372/4885HPGD 4261/4885 |
| US-20230133667-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | NPC1 1905/4885RAB9A 2372/4885HPGD 4261/4885 |
| US-20230114674-A1 | ISOINDOLINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | CRBN, CREBBP, CDR2 | NPC1 437/4885RAB9A 3792/4885HPGD 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.